Volume may soon grow further as Novo Nordisk pursues Ablynx. Novo went public with its $3.2-billion offer for the maker of an experimental treatment for a rare blood disorder after being turned down. Ablynx's biggest investor has said he might be receptive to a higher bid. The purchase would be Novo's biggest ever, and the Danish company has said it's reviewing other potential takeovers to look for new medicines.

Source: Los Angeles Times January 22, 2018 19:41 UTC